未接种和已接种新冠疫苗的类风湿关节炎患者感染COVID-19的风险:一项普通人群研究
基于英国初级保健数据库的两项队列研究比较类风湿关节炎(RA)患者与普通人群在接种与未接种新冠疫苗状态下SARS-CoV-2感染、住院和死亡风险。未接种者随访3个月,RA患者感染、住院和死亡风险均更高;接种者随访9个月,突破性感染和住院风险仍较高,但3个月和6个月随访时未见明显差异。
要点
- 未接种疫苗的RA患者随访3个月,感染、住院和死亡风险均高于普通人群。
- 已接种疫苗的RA患者随访9个月,突破性感染和住院风险仍高于普通人群。
- 已接种疫苗的RA患者随访3个月和6个月时,上述结局风险与普通人群未见明显差异。
核心结论
- RA患者接种新冠疫苗后,SARS-CoV-2感染和COVID-19住院风险仍高于普通人群。
- 这些发现支持在RA患者中推广新冠疫苗加强接种并坚持其他预防策略。
研究设计与样本
- 基于英国初级保健数据库开展两项队列研究,比较RA患者与普通人群按新冠疫苗接种状态划分的SARS-CoV-2感染、住院和死亡风险。
- 采用暴露评分重叠权重平衡两个比较队列的基线特征。
主要发现
- 未接种者随访3个月,RA患者与普通人群的加权感染率分别为9.21/1000人月 vs 8.16/1000人月(HR 1.10,95%CI 1.00-1.24)。
- 未接种者随访3个月,RA患者与普通人群的加权住院率分别为3.46/1000人月 vs 2.14/1000人月(HR 1.62,95%CI 1.34-1.96)。
- 未接种者随访3个月,RA患者与普通人群的加权死亡率分别为1.19/1000人月 vs 0.62/1000人月(HR 1.88,95%CI 1.37-2.60)。
- 已接种者随访9个月,RA患者与普通人群的加权突破性感染率分别为4.17/1000人月 vs 3.96/1000人月(HR 1.10,95%CI 1.00-1.20)。
- 已接种者随访9个月,RA患者与普通人群的加权住院率分别为0.42/1000人月 vs 0.32/1000人月(HR 1.29,95%CI 0.96-1.75);随访3个月和6个月时两组上述结局风险未见明显差异。
临床怎么用
- 作者认为这些发现支持在RA患者中推广新冠疫苗加强接种并坚持其他预防策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether patients with rheumatoid arthritis (RA) are at higher risks for SARS-CoV-2 infection and its severe outcomes before and after COVID-19 vaccination. METHODS: Using a UK primary care database, we conducted 2 cohort studies to compare the risks of SARS-CoV-2 infection, hospitalization, and death from COVID-19 between patients with RA and the general population according to their COVID-19 vaccination status. We used exposure score overlap weighting to balance baseline characteristics between 2 comparison cohorts. RESULTS: Among unvaccinated individuals, the weighted incidence rates of SARS-CoV-2 infection (9.21 versus 8.16 of 1,000 person-months), hospitalization (3.46 versus 2.14 of 1,000 person-months), and death (1.19 versus 0.62 of 1,000 person-months) were higher among patients with RA than the general population over 3 months of follow-up; the corresponding adjusted hazard ratios (HRs) were 1.10 (95% confidence interval [95% CI] 1.00-1.24), 1.62 (95% CI 1.34-1.96), and 1.88 (95% CI 1.37-2.60), respectively. Among vaccinated individuals, the weighted rates of breakthrough infection (4.17 versus 3.96 of 1,000 person-months; HR 1.10 [95% CI 1.00-1.20]) and hospitalization (0.42 versus 0.32 of 1,000 person-months; HR 1.29 [95% CI 0.96-1.75]) were higher among patients with RA than the general population over 9 months of follow-up; however, no apparent difference in the risk of these outcomes was observed over 3 and 6 months of follow-up between 2 comparison cohorts. CONCLUSION: Patients with RA are still at higher risks of SARS-CoV-2 infection and COVID-19 hospitalization than the general population after receiving COVID-19 vaccines. These findings support booster COVID-19 vaccinations and adherence of other preventive strategies among patients with RA.
引用
- Li H, Wallace ZS, Sparks JA, et al. Risk of COVID-19 Among Unvaccinated and Vaccinated Patients With Rheumatoid Arthritis: A General Population Study. Arthritis Care Res (Hoboken). 2022. PMID: 36161711. doi:10.1002/acr.25028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。